Zoledronic acid for breast cancer bone metastases
Part of Bones, joints & muscles, Cancer clinical trials.
This real-world study looks at how the medicine zoledronic acid affects bone-related problems in people with breast cancer that has spread to the bone. It may help reduce events like fractures or other bone complications by protecting bone health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- You have confirmed breast cancer, and scans (MRI or CT) first showed bone metastases.
- You have already started zoledronic acid treatment for the bone metastases.
- Your kidneys are working well enough for the study (creatinine and kidney filtration meet limits).
- Your blood calcium level is between about 2.0 and 3.0 (with the lab’s units).
- Your daily-function score (ECOG) is 0 to 2, meaning you can do limited self-care/activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how the body handles a medicine called zoledronic acid in people with kidney disease who are on dialysis and have weak bones (osteoporosis). It may help doctors find the right dose to safely treat bone loss in this group.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This trial tests a new drug, JMT103, against a standard treatment (zoledronic acid) to see if it better prevents bone problems in people whose cancer has spread to the bones. If you have breast, prostate, lung, or another solid tumor with bone metastases, this study may be an option.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This trial tests if zoledronate, a medicine that strengthens bones, can reduce pain in children with CRMO (a condition causing repeated bone inflammation). It compares zoledronate to a placebo (inactive treatment) to see if it helps after 12 weeks.
Hear when a new Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.